
Massimo Gennarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9188719/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide association studies on Northern Italy isolated populations provide further support concerning genetic susceptibility for major depressive disorder. World Journal of Biological Psychiatry, 2023, 24, 135-148.	2.6	1
2	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 46-54.	2.6	4
3	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2022, 55, 86-95.	0.7	19
4	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. European Neuropsychopharmacology, 2022, 55, 112-157.	0.7	7
5	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
6	Genetic Dissection of Temperament Personality Traits in Italian Isolates. Genes, 2022, 13, 4.	2.4	2
7	Extracellular clusterin limits the uptake of αâ€synuclein fibrils by murine and human astrocytes. Glia, 2021, 69, 681-696.	4.9	32
8	Biological correlates of early life stressful events in major depressive disorder. Psychoneuroendocrinology, 2021, 125, 105103.	2.7	23
9	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. Pharmacogenomics Journal, 2021, 21, 85-93.	2.0	1
10	Alterations observed in the interferon α and β signaling pathway in MDD patients are marginally influenced by cis-acting alleles. Scientific Reports, 2021, 11, 727.	3.3	1
11	Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19. Pharmacological Research, 2021, 164, 105402.	7.1	1
12	Classification of Psychoses Based on Immunological Features: A Machine Learning Study in a Large Cohort of First-Episode and Chronic Patients. Schizophrenia Bulletin, 2021, 47, 1141-1155.	4.3	11
13	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. Stem Cell Research, 2021, 51, 102216.	0.7	2
14	Intermediate lengths of the C9ORF72 hexanucleotide repeat expansion may synergistically contribute to attention deficit hyperactivity disorder in child and his father: case report. Neurocase, 2021, 27, 138-146.	0.6	2
15	Evidence of an interaction between <i>FXR1</i> and <i>GSK3β</i> polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. European Psychiatry, 2021, 64, e39.	0.2	6
16	Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years. Biochemical Society Transactions, 2021, 49, 1375-1384.	3.4	6
17	Whole Blood Transcriptome Characterization of 3xTg-AD Mouse and Its Modulation by Transcranial Direct Current Stimulation (tDCS). International Journal of Molecular Sciences, 2021, 22, 7629.	4.1	4
18	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. Brain Sciences, 2021, 11, 1120.	2.3	11

#	Article	IF	CITATIONS
19	Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. Journal of Personalized Medicine, 2021, 11, 1100.	2.5	3
20	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. Högre Utbildning, 2021, 12, 1987655.	3.0	16
21	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq1 1 0	.7841361.4 rg	gBT 2 Overlock
22	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	3.2	22
23	Childhood trauma and glucose metabolism in patients with first-episode psychosis. Psychoneuroendocrinology, 2020, 113, 104536.	2.7	15
24	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in firstâ€episode psychosis. Microbial Biotechnology, 2020, 14, 507-511.	1.7	15
25	P.264 Association of single nucleotide polymorphisms in the 3' untranslated region of SLC1A2 with major depressive disorder and relative endophenotypes. European Neuropsychopharmacology, 2020, 40, S150-S151.	0.7	Ο
26	Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol. Alzheimer's Research and Therapy, 2020, 12, 152.	6.2	7
27	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. Genes, 2020, 11, 1089.	2.4	17
28	Behavioral and Psychological Symptoms of Dementia (BPSD): Clinical Characterization and Genetic Correlates in an Italian Alzheimer's Disease Cohort. Journal of Personalized Medicine, 2020, 10, 90.	2.5	15
29	The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms. Frontiers in Genetics, 2020, 11, 826.	2.3	28
30	Assessment of haptoglobin alleles in autism spectrum disorders. Scientific Reports, 2020, 10, 7758.	3.3	2
31	Association study between <scp><i>HTR2A</i></scp> rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Development Research, 2020, 81, 754-761.	2.9	15
32	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. Drug Development Research, 2020, 81, 593-599.	2.9	14
33	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. Frontiers in Aging Neuroscience, 2020, 11, 366.	3.4	17
34	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. Stem Cell Research, 2020, 49, 102104.	0.7	1
35	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2019, 82, 102-109.	3.1	76
36	F49GENETIC DETERMINANTS OF CIRCULATING VEGF LEVELS IN MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S1135-S1136.	0.7	0

#	Article	IF	CITATIONS
37	Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. Frontiers in Pharmacology, 2019, 10, 402.	3.5	35
38	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. Journal of ECT, 2019, 35, 189-194.	0.6	19
39	α-Synuclein and Clia in Parkinson's Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?. Cellular and Molecular Neurobiology, 2019, 39, 161-168.	3.3	40
40	Next Generation Sequencing Analysis in Early Onset Dementia Patients. Journal of Alzheimer's Disease, 2019, 67, 243-256.	2.6	29
41	Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain, Behavior, and Immunity, 2018, 70, 315-324.	4.1	31
42	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. World Journal of Biological Psychiatry, 2018, 19, 610-618.	2.6	12
43	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Molecular Neurobiology, 2018, 55, 1054-1067.	4.0	30
44	Genome-wide analysis of consistently RNA edited sites in human blood reveals interactions with mRNA processing genes and suggests correlations with cell types and biological variables. BMC Genomics, 2018, 19, 963.	2.8	8
45	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2307-2312.	2.2	7
46	A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme. Scientific Reports, 2018, 8, 15470.	3.3	17
47	The effect of childhood trauma on blood transcriptome expression in major depressive disorder. Journal of Psychiatric Research, 2018, 104, 50-54.	3.1	14
48	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plasticity, 2018, 2018, 1-15.	2.2	31
49	Non-Ceruloplasmin Copper Distincts Subtypes in Alzheimer's Disease: a Genetic Study of ATP7B Frequency. Molecular Neurobiology, 2017, 54, 671-681.	4.0	40
50	The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. Pharmacogenomics Journal, 2017, 17, 146-154.	2.0	37
51	Compound heterozygosity for a hemizygous rare missense variant (rs141999351) and a large CNV deletion affecting the FSTL5 gene in a patient with schizophrenia. Psychiatry Research, 2017, 258, 598-599.	3.3	1
52	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. Molecular and Cellular Neurosciences, 2017, 85, 220-225.	2.2	11
53	Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. Journal of Affective Disorders, 2017, 208, 443-447.	4.1	15
54	Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways. PLoS ONE, 2017, 12, e0182778.	2.5	14

#	Article	IF	CITATIONS
55	Acute Footshock Stress Induces Time-Dependent Modifications of AMPA/NMDA Protein Expression and AMPA Phosphorylation. Neural Plasticity, 2016, 2016, 1-10.	2.2	27
56	Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response. Journal of ECT, 2016, 32, 88-92.	0.6	47
57	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18
58	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. Journal of Affective Disorders, 2016, 200, 250-258.	4.1	138
59	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. Neuropsychobiology, 2016, 74, 15-21.	1.9	8
60	Influence of GRIK4 genetic variants on the electroconvulsive therapy response. Neuroscience Letters, 2016, 626, 94-98.	2.1	10
61	The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia. Current Neuropharmacology, 2016, 14, 540-550.	2.9	16
62	The role of <i>GRIK4</i> gene in treatment-resistant depression. Genetical Research, 2015, 97, e14.	0.9	19
63	Copper Subtype of Alzheimer Disease: A Genetic Study of ATP7B Frequency. American Journal of Clinical Pathology, 2015, 144, A242-A242.	0.7	Ο
64	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. PLoS ONE, 2015, 10, e0116686.	2.5	65
65	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. Journal of Affective Disorders, 2015, 183, 179-186.	4.1	17
66	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. Translational Psychiatry, 2015, 5, e687-e687.	4.8	26
67	The role of the potassium channel gene KCNK2 in major depressive disorder. Psychiatry Research, 2015, 225, 489-492.	3.3	10
68	Glucose metabolism alterations in patients with bipolar disorder. Journal of Affective Disorders, 2015, 184, 293-298.	4.1	34
69	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. Journal of Molecular Neuroscience, 2015, 56, 681-687.	2.3	35
70	Copy number variants in attention-deficit hyperactive disorder. Psychiatric Genetics, 2015, 25, 59-70.	1.1	25
71	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatrica Scandinavica, 2014, 129, 461-466.	4.5	34
72	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Frontiers in Cellular Neuroscience, 2014, 8, 75.	3.7	100

#	Article	IF	CITATIONS
73	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit–hyperactivity disorder (ADHD). European Child and Adolescent Psychiatry, 2014, 23, 173-177.	4.7	40
74	Defining an immune signature predictive of glioma progression. Journal of Neuroimmunology, 2014, 275, 35.	2.3	0
75	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	3.1	134
76	Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. Neurobiology of Aging, 2014, 35, 1206-1211.	3.1	9
77	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. BioTechniques, 2014, 57, 111-114.	1.8	34
78	P4-074: ITALIAN NETWORK FOR AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION (ITALIANDIAFN). , 2014, 10, P810-P810.		0
79	Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1genes. BMC Medical Genetics, 2013, 14, 33.	2.1	26
80	Glucocorticoid-Related Molecular Signaling Pathways Regulating Hippocampal Neurogenesis. Neuropsychopharmacology, 2013, 38, 872-883.	5.4	262
81	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
82	Molecular signature of disease onset in Granulin mutation carriers: a gene expression analysis study. Neurobiology of Aging, 2013, 34, 1837-1845.	3.1	19
83	Blood microRNA changes in depressed patients during antidepressant treatment. European Neuropsychopharmacology, 2013, 23, 602-611.	0.7	197
84	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. BioMed Research International, 2013, 2013, 1-7.	1.9	137
85	Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8708-8713.	7.1	272
86	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. Depression and Anxiety, 2013, 30, 1170-1176.	4.1	42
87	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline †Predictors' and Longitudinal †Targets'. Neuropsychopharmacology, 2013, 38, 377-385.	5.4	372
88	Cannabis and Psychosis: A Systematic Review of Genetic Studies. Current Psychiatry Reviews, 2013, 9, 302-315.	0.9	6
89	Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia. American Journal of Human Genetics, 2012, 91, 303-312.	6.2	81
90	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics Journal, 2012, 12, 68-77.	2.0	92

#	Article	IF	CITATIONS
91	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2012, 13, 73.	1.6	47
92	Biomarkers and Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 1003-1019.e20.	0.5	192
93	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. BMC Psychiatry, 2012, 12, 145.	2.6	16
94	Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 29, 699-705.	2.6	20
95	Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurological Sciences, 2012, 33, 375-378.	1.9	20
96	PCLO gene: Its role in vulnerability to major depressive disorder. Journal of Affective Disorders, 2012, 139, 250-255.	4.1	20
97	Antidepressant Treatments Change 5-HT2C Receptor mRNA Expression in Rat Prefrontal/Frontal Cortex and Hippocampus. Neuropsychobiology, 2011, 63, 160-168.	1.9	38
98	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochemistry International, 2011, 59, 896-905.	3.8	61
99	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1322-1325.	4.8	73
100	Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. Neurobiology of Aging, 2011, 32, 555.e1-555.e8.	3.1	39
101	Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	2.0	29
102	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2011, 35, no-no.	2.4	36
103	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 323-329.	3.2	54
104	The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. BMC Psychiatry, 2011, 11, 50.	2.6	39
105	Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of Psychopharmacology, 2011, 25, 867-874.	4.0	44
106	Genetic Background Predicts Poor Prognosis in Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2011, 8, 289-295.	1.4	17
107	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. International Journal of Neuropsychopharmacology, 2010, 13, 103.	2.1	82
108	Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. Psychiatric Genetics, 2010, 20, 44-45.	1.1	4

#	Article	IF	CITATIONS
109	VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. Journal of Alzheimer's Disease, 2010, 21, 87-94.	2.6	12
110	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	3.6	44
111	Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. Neurobiology of Disease, 2010, 37, 747-755.	4.4	107
112	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. BMC Neuroscience, 2010, 11, 16.	1.9	16
113	Serum levels of brain-derived neurotrophic factor in drug-naÃ⁻ve obsessive–compulsive patients: A case–control study. Journal of Affective Disorders, 2010, 122, 174-178.	4.1	76
114	New Copy Number Variations in Schizophrenia. PLoS ONE, 2010, 5, e13422.	2.5	82
115	Genetic Variations and Association. International Review of Neurobiology, 2010, 94, 129-151.	2.0	0
116	The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study. NeuroImmunoModulation, 2010, 17, 126-131.	1.8	35
117	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. World Journal of Biological Psychiatry, 2010, 11, 763-773.	2.6	363
118	Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: Comparison with methylphenidate. Pharmacological Research, 2010, 62, 523-529.	7.1	60
119	Clinical and medial temporal features in a family with mood disorders. Neuroscience Letters, 2010, 468, 93-97.	2.1	23
120	Serotonin transporter gene polymorphisms and treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 934-939.	4.8	38
121	The Expression of VGF is Reduced in Leukocytes of Depressed Patients and it is Restored by Effective Antidepressant Treatment. Neuropsychopharmacology, 2010, 35, 1423-1428.	5.4	68
122	Long-Term Duloxetine Treatment Normalizes Altered Brain-Derived Neurotrophic Factor Expression in Serotonin Transporter Knockout Rats through the Modulation of Specific Neurotrophin Isoforms. Molecular Pharmacology, 2010, 77, 846-853.	2.3	56
123	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. PLoS Genetics, 2009, 5, e1000373.	3.5	383
124	An Association of GRIK3 Ser310Ala Functional Polymorphism with Personality Traits. Neuropsychobiology, 2009, 59, 28-33.	1.9	16
125	Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neuroscience, 2009, 10, 48.	1.9	53
126	Mutation within <i>TARDBP</i> leads to Frontotemporal Dementia without motor neuron disease. Human Mutation, 2009, 30, E974-E983.	2.5	220

#	Article	IF	CITATIONS
127	Genetic Variation in the G720/G30 Gene Locus (DAOA) Influences the Occurrence of Psychotic Symptoms in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 953-960.	2.6	24
128	VEGF serum levels in depressed patients during SSRI antidepressant treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 146-149.	4.8	61
129	Acute Stress Responsiveness of the Neurotrophin BDNF in the Rat Hippocampus is Modulated by Chronic Treatment with the Antidepressant Duloxetine. Neuropsychopharmacology, 2009, 34, 1523-1532.	5.4	104
130	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.8	80
131	Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia. Psychiatric Genetics, 2009, 19, 237-243.	1.1	12
132	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics, 2008, 9, 197-205.	1.4	63
133	Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 745-753.	1.7	31
134	Reduced activation of intracellular signaling pathways in rat prefrontal cortex after chronic phencyclidine administration. Pharmacological Research, 2008, 57, 296-302.	7.1	14
135	Effect of the Xbal polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neuroscience Letters, 2008, 434, 304-309.	2.1	8
136	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters, 2008, 437, 130-134.	2.1	79
137	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 712-715.	1.9	12
138	Chronic Duloxetine Treatment Induces Specific Changes in the Expression of BDNF Transcripts and in the Subcellular Localization of the Neurotrophin Protein. Neuropsychopharmacology, 2007, 32, 2351-2359.	5.4	110
139	Risk Prediction for Clinical Phenotype in Myotonic Dystrophy Type 1: Data from 2,650 Patients. Genetic Testing and Molecular Biomarkers, 2007, 11, 84-90.	1.7	46
140	Further evidence on the lack of association between glycogen synthase kinase 3β gene polymorphisms and bipolar disorder. Psychiatric Genetics, 2007, 17, 249-250.	1.1	6
141	A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case–control study. Psychiatric Genetics, 2007, 17, 355-356.	1.1	5
142	Long-term soluble Aβ1–40 activates CaM kinase II in organotypic hippocampal cultures. Neurobiology of Aging, 2007, 28, 1388-1395.	3.1	10
143	-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study. Brain, Behavior, and Immunity, 2007, 21, 450-457.	4.1	44
144	Dementia, delusions and seizures: storage disease or genetic AD?. European Journal of Neurology, 2007, 14, 1057-1059.	3.3	31

#	Article	IF	CITATIONS
145	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology, 2006, 16, 620-624.	0.7	149
146	Regulation of Editing and Expression of Glutamate α-Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs. Biological Psychiatry, 2006, 59, 713-720.	1.3	92
147	The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neuroscience Letters, 2006, 406, 133-137.	2.1	58
148	No association between Ala9Val functional polymorphism of MnSOD gene and schizophrenia in a representative Italian sample. Neuroscience Letters, 2006, 410, 208-211.	2.1	12
149	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 10, 371-378.	2.6	30
150	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. European Journal of Human Genetics, 2006, 14, 443-449.	2.8	33
151	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. Journal of Affective Disorders, 2006, 91, 83-86.	4.1	137
152	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 1-4.	1.7	39
153	Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?. Clinical Neurophysiology, 2005, 116, 1062-1071.	1.5	78
154	Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine, 2005, 30, 293-302.	3.2	58
155	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiology of Aging, 2005, 26, 455-464.	3.1	43
156	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer's Disease. Aging Clinical and Experimental Research, 2005, 17, 445-448.	2.9	9
157	Selective Phosphorylation of Nuclear CREB by Fluoxetine is Linked to Activation of CaM Kinase IV and MAP Kinase Cascades. Neuropsychopharmacology, 2004, 29, 1831-1840.	5.4	171
158	Association Study of –1727 A/T, –50 C/T and (CAA) _n Repeat GSK-3β Gene Polymorphisms with Schizophrenia. Neuropsychobiology, 2004, 50, 16-20.	1.9	29
159	Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biological Psychiatry, 2004, 55, 1095-1102.	1.3	99
160	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neuroscience Letters, 2004, 356, 119-122.	2.1	49
161	3′ UTR (AGG)n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. Neuroscience Letters, 2004, 357, 235-237.	2.1	24
162	Expression and phosphorylation of Î-CaM kinase II in cultured Alzheimer fibroblasts. Neurobiology of Aging, 2004, 25, 1187-1196.	3.1	7

#	Article	IF	CITATIONS
163	Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. NeuroReport, 2004, 15, 2109-2112.	1.2	66
164	Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. NeuroReport, 2004, 15, 2393-2396.	1.2	37
165	Association between IL-1β -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. Journal of Psychiatric Research, 2003, 37, 457-462.	3.1	52
166	Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. Journal of Neuroscience Research, 2003, 72, 622-628.	2.9	68
167	Dopaminergic D2 receptor activation modulates FGFâ€2 gene expression in rat prefrontal cortex and hippocampus. Journal of Neuroscience Research, 2003, 74, 74-80.	2.9	26
168	Atypical dementia associated with a novel presenilinâ€⊋ mutation. Annals of Neurology, 2003, 54, 832-836.	5.3	51
169	Selective regulation of presynaptic Calcium/Calmodulin-Dependent protein kinase II by psychotropic drugs. Biological Psychiatry, 2003, 53, 442-449.	1.3	36
170	Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biological Psychiatry, 2003, 53, 617-619.	1.3	57
171	Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. Neurobiology of Aging, 2003, 24, 933-939.	3.1	58
172	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. Neuropsychobiology, 2002, 46, 17-21.	1.9	27
173	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biological Psychiatry, 2002, 51, 480-484.	1.3	81
174	Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clinical Genetics, 2002, 59, 344-349.	2.0	48
175	Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disorders, 2002, 4, 166-182.	1.9	110
176	Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biological Psychiatry, 2001, 50, 117-122.	1.3	50
177	Long-term treatment with s-adenosylmethionine induces changes in presynaptic cam kinase II and synapsin I. Biological Psychiatry, 2001, 50, 337-344.	1.3	11
178	Human Y-chromosome variation in the Western Mediterranean area: implications for the peopling of the region. Human Immunology, 2001, 62, 871-884.	2.4	79
179	Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity. Brain Research Reviews, 2001, 37, 249-258.	9.0	92
180	Decreased hippocampal BDNF expression after acute systemic injection of quinpirole. Neuropharmacology, 2001, 40, 954-957.	4.1	11

#	Article	IF	CITATIONS
181	Combined α2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. Psychopharmacology, 2001, 159, 105-110.	3.1	16
182	Stimulatory role of dopamine on fibroblast growth factorâ€⊋ expression in rat striatum. Journal of Neurochemistry, 2001, 76, 990-997.	3.9	48
183	Association between â^G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Molecular Psychiatry, 2001, 6, 79-82.	7.9	172
184	Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders. , 2001, 89, 149-170.		28
185	Prenatal Diagnosis of Myotonic Dystrophy Using Fetal DNA Obtained from Maternal Plasma. Clinical Chemistry, 2000, 46, 301-302.	3.2	201
186	Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression. Human Molecular Genetics, 1999, 8, 1017-1023.	2.9	38
187	Reduction of the DM-associated homeo domain protein (DMAHP) mRNA in different brain areas of myotonic dystrophy patients. Neuromuscular Disorders, 1999, 9, 215-219.	0.6	18
188	Cognitive impairment and (CTG)n expansion in myotonic dystrophy patients. Biological Psychiatry, 1999, 46, 425-431.	1.3	67
189	Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity. , 1998, 16, 117-122.		3
190	A Single Polymerase Chain Reaction-Based Protocol for Detecting Normal and Expanded Alleles in Myotonic Dystrophy. Diagnostic Molecular Pathology, 1998, 7, 135-137.	2.1	27
191	Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. FEBS Letters, 1997, 401, 53-58.	2.8	35
192	Expression Study of Survival Motor Neuron Gene in Human Fetal Tissues. Biochemical and Molecular Medicine, 1997, 61, 102-106.	1.4	31
193	Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Italian Journal of Neurological Sciences, 1996, 17, 59-65.	0.1	28
194	Correlation of Sfil macrorestriction endonuclease fingerprint analysis of Candida parapsilosis isolates with source of isolation. Journal of Medical Microbiology, 1996, 45, 173-178.	1.8	19
195	Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization. Cytogenetic and Genome Research, 1996, 74, 187-188.	1.1	5
196	Two pedigrees of autosomal dominant atrioventricular canal defect (AVCD): Exclusion from the critical region on 8p. American Journal of Medical Genetics Part A, 1995, 57, 483-488.	2.4	18
197	Postzygotic instability of the myotonic dystrophy p[AGC]n repeat supported by larger expansions in muscle and reduced amplifications in sperm. Journal of Neurology, 1995, 242, 379-383.	3.6	13
198	Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Human Molecular Genetics, 1995, 4, 599-606.	2.9	179

#	Article	IF	CITATIONS
199	Discordant clinical outcome in myotonic dystrophy relatives showing (CTG)n > 700 repeats. Neuromuscular Disorders, 1995, 5, 157-159.	0.6	21
200	Identification of Multiple Transcribed Sequences from the Spinal Muscular Atrophy Region on Human Chromosome 5. Biochemical and Biophysical Research Communications, 1995, 206, 294-301.	2.1	7
201	Survival Motor-Neuron Gene Transcript Analysis in Muscles from Spinal Muscular-Atrophy Patients. Biochemical and Biophysical Research Communications, 1995, 213, 342-348.	2.1	182
202	Different Expression of the Myotonin Protein Kinase Gene in Discrete Areas of Human Brain. Biochemical and Biophysical Research Communications, 1995, 216, 489-494.	2.1	9
203	Exclusion of linkage with chromosome 21 in families with recurrence of non-Down's atrioventricular canal. Human Genetics, 1994, 94, 708-10.	3.8	14
204	First-trimester prenatal diagnosis of spinal muscular atrophy using microsatellite markers. Prenatal Diagnosis, 1994, 14, 459-462.	2.3	12
205	North Eurasian origin of the myotonic dystrophy mutation. Human Mutation, 1994, 4, 79-81.	2.5	6
206	High conservation of the trinucleotide [CTG]n repeat at the myotonic dystrophy locus in nonhuman primates. Human Evolution, 1994, 9, 315-321.	2.0	0
207	Male Hypogonadism in Myotonic Dystrophy is Related to (Ctg)N Triplet Mutation. Journal of Endocrinological Investigation, 1994, 17, 381-383.	3.3	37
208	(CTG)n Triplet Mutation and Phenotype Manifestations in Myotonic Dystrophy Patients. Biochemical Medicine and Metabolic Biology, 1993, 50, 85-92.	0.7	47
209	Human Elongation Factor EF-11 ² : Cloning and Characterization of the EF11 ² 5a Gene and Assignment of EF-11 ² Isoforms to Chromosomes 2, 5, 15, and X. Biochemical and Biophysical Research Communications, 1993, 197, 154-162.	2.1	23
210	A tool for the molecular analysis of an early lethal disease: slide-PCR in spinal muscular atrophy patients. Molecular and Cellular Probes, 1993, 7, 221-226.	2.1	7
211	Focus The dynamic genomics of myotonic dystrophy and its clinical relevance: an overview. Biomedicine and Pharmacotherapy, 1993, 47, 321-330.	5.6	5
212	Expansion of the myotonic dystrophy gene in Italian and Spanish patients Journal of Medical Genetics, 1992, 29, 789-790.	3.2	8
213	Inosine-containing primers in human papillomavirus detection by polymerase chain reaction. Biomedicine and Pharmacotherapy, 1992, 46, 167-169.	5.6	6
214	Assignment of the slow troponin T (TNNT1) gene to chromosome 19 using polymerase chain reaction. Human Genetics, 1992, 88, 697-698.	3.8	5
215	Analysis of apoB, HLADQ alpha, and D1S80 polymorphisms in the Italian population using the polymerase chain reaction. American Journal of Human Biology, 1992, 4, 381-386.	1.6	17
216	Genotyping of spinal muscular atrophy families with linked DNA probes. Clinical Genetics, 1992, 42, 317-319.	2.0	2

#	Article	IF	CITATIONS
217	Study of the effects on DNA of electromagnetic fields using clamped homogeneous electric field gel electrophoresis. Biomedicine and Pharmacotherapy, 1991, 45, 451-454.	5.6	5
218	3? creatine kinase (M-type) polymorphisms linked to myotonic dystrophy in Italian and Spanish populations. Human Genetics, 1991, 87, 654-6.	3.8	10